19-24 August 2018
Daegu, South Korea
Sabine Specht, Head of Filarial Clinical Programme, DNDi – session on filariasis
Jean-Robert Ioset, Senior Discovery Manager, DNDi – session on drug discovery
19-24 August 2018
19-20 June 2018
Ben Perry, Senior Discovery Manager – presentation on the NTD Drug Discovery Booster
The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.
Daiichi Sankyo RD Novare and DNDi are pleased to announce the financial support of the Japan Global Health Innovative Technology Fund to their new collaboration on natural products.
by Van den Kerkhof M, Mabille D, Chatelain E, Mowbray CE, Braillard S, Hendrickx S, Maes L, Caljon G.
International Journal for Parasitology: Drugs and Drug Resistance, April 2018
Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.
Drug Discovery News [14 March 2018]
“Working the crowd”
by Eberhardt E, Van den Kerkhof M, Bulté D, Mabille D, Van Bockstal L, Monnerat S, Alves F, Mbui J, Delputte P, Cos P, Hendrickx S, Maes L, Caljon G.
Journal of Molecular Diagnostics, March 2018
by Thompson AM, O’Connor PD, Marshall AJ, Blaser A, Yardley V, Maes L, Gupta S, Launay D, Braillard S, Chatelain E, Wan B, Franzblau SG, Ma Z, Cooper CB, and Denny WA.
Journal of Medicinal Chemistry, February 2018
Africa Science Gateway [15 February 2018]
“DNDi and partners in new platform to defeat mycetoma”
Brazilian Society of Tropical Medicine [14 February 2018]
“The quest for new drugs for forgotten populations is a priority, says Jadel Kratz”
Global Health NOW [8 February 2018]
“An open pharma approach targets a terrible disease”
IP Watch [7 February 2018]
“New open source drug discovery initiative takes aim at ‘devastating’ disease”
Science & Entreprise [7 February 2018]
“Open-source discovery seeks neglected disease drug”
Computerworld [7 February 2018]
“Researchers look to open source to tackle deadly infection”
Geneva, Rotterdam, Sydney – 6 February 2018
The MycetOS (Mycetoma Open Source) project was launched today by the University of Sydney, Erasmus MC, and DNDi to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.
5-8 March 2018
Jadel Kratz, LOLA Coordinator, DNDi Latin America – presentation of a poster on collaborative R&D networks for NTDs in endemic areas
Dr Robert Don, Discovery and Pre-Clinical Director at DNDi (2005-2017), reflects on challenges and achievements in drug discovery at DNDi over the last 12 years.
by Chatelain E, Ioset JR.
Expert Opinion on Drug Discovery, December 2017